BIO-TECHNE CORP shareholders Q4 2021

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Palisade Asset Management, LLC 14,336$7,417,0000.83%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 583,529$301,883,0000.82%
Covea Finance 17,223$8,910,0000.78%
Formidable Asset Management, LLC 7,925$3,726,0000.72%
LEAVELL INVESTMENT MANAGEMENT, INC. 20,631$10,673,0000.71%
PATTON FUND MANAGEMENT, INC. 4,172$2,158,0000.66%
Paradigm, Strategies in Wealth Management, LLC 1,208$625,0000.63%
Lisanti Capital Growth, LLC 8,195$4,240,0000.61%
Arabesque Asset Management Ltd 3,884$2,009,0000.58%
Morse Asset Management, Inc 4,998$2,586,0000.58%
MARSHALL WACE, LLP 580,835$300,491,0000.56%
Sweet Financial Partners, LLC 2,420$1,252,0000.52%
BRIDGER MANAGEMENT, LLC 7,190$3,720,0000.48%
MCKINLEY CAPITAL MANAGEMENT LLC 10,230$5,292,0000.47%
Fulcrum Equity Management 2,290$1,185,0000.44%
Neuberger Berman Group LLC 1,096,671$560,483,0000.44%
Pluribus Labs, LLC 803$415,0000.44%
Conestoga Capital Advisors, LLC 64,744$33,495,0000.44%
Tevis Investment Management 946$490,0000.43%
Gitterman Wealth Management, LLC 1,109$574,0000.43%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q4 2021. To view BIO-TECHNE CORP's shareholder history, click here.